BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Acquired by Prudential Financial Inc.

Prudential Financial Inc. grew its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 10.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 983,033 shares of the biotechnology company’s stock after acquiring an additional 90,603 shares during the quarter. Prudential Financial Inc. owned about 0.47% of BioCryst Pharmaceuticals worth $7,392,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. lifted its holdings in BioCryst Pharmaceuticals by 7.8% in the 4th quarter. Vanguard Group Inc. now owns 21,890,422 shares of the biotechnology company’s stock valued at $164,616,000 after purchasing an additional 1,583,826 shares in the last quarter. Hillsdale Investment Management Inc. raised its position in shares of BioCryst Pharmaceuticals by 65,213.3% in the fourth quarter. Hillsdale Investment Management Inc. now owns 542,100 shares of the biotechnology company’s stock valued at $4,077,000 after buying an additional 541,270 shares during the last quarter. BNP Paribas Financial Markets lifted its stake in shares of BioCryst Pharmaceuticals by 472.0% in the third quarter. BNP Paribas Financial Markets now owns 496,784 shares of the biotechnology company’s stock worth $3,776,000 after buying an additional 409,938 shares in the last quarter. Principal Financial Group Inc. boosted its position in BioCryst Pharmaceuticals by 1,058.1% during the third quarter. Principal Financial Group Inc. now owns 411,414 shares of the biotechnology company’s stock worth $3,127,000 after acquiring an additional 375,890 shares during the last quarter. Finally, Cinctive Capital Management LP purchased a new stake in BioCryst Pharmaceuticals during the 3rd quarter valued at about $2,082,000. 85.88% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

BCRX has been the topic of a number of research reports. Royal Bank of Canada reissued an “outperform” rating and issued a $11.00 target price (up from $10.00) on shares of BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. Needham & Company LLC boosted their price objective on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the stock a “buy” rating in a research note on Monday, January 13th. HC Wainwright restated a “buy” rating and issued a $30.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. Evercore ISI lifted their price target on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an “outperform” rating in a report on Monday, January 13th. Finally, Wedbush initiated coverage on shares of BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. They set an “outperform” rating and a $15.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, BioCryst Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $15.57.

BioCryst Pharmaceuticals Trading Up 0.4 %

NASDAQ BCRX opened at $7.86 on Friday. The stock has a market cap of $1.64 billion, a PE ratio of -12.89 and a beta of 1.85. The stock has a fifty day simple moving average of $8.18 and a 200-day simple moving average of $7.82. BioCryst Pharmaceuticals, Inc. has a twelve month low of $4.03 and a twelve month high of $9.50.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings results on Monday, February 24th. The biotechnology company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The firm had revenue of $131.50 million during the quarter, compared to analyst estimates of $126.64 million. The firm’s revenue for the quarter was up 40.8% on a year-over-year basis. During the same period in the prior year, the company posted $0.28 EPS. Research analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current year.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.